Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: A competing risks modeling approach

Journal of the American Society of Nephrology

Volumn 16, Issue 8, 2005, Pages 2449-2455

  Ravani, Pietro ^a   Tripepi, Giovanni ^b   Malberti, Fabio ^a   Testa, Sophie ^a   Mallamaci, Francesca ^b   Zoccali, Carmine ^b  

^a CREMONA HOSPITAL   (Italy)

^b CNR Consiglio Nazionale delle Ricerche   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HEMOGLOBIN; HOMOCYSTEINE; N(G),N(G) DIMETHYLARGININE;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CHRONIC KIDNEY DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; DIALYSIS; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA;

EID: 28444435118     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2005010076     Document Type: Article

References (36)

1. Cooke JP: Asymmetrical dimethylarginine: The Uber marker? Circulation 109: 1813-1818, 2004
2. Masuda H, Goto M, Tamaoki S, Azuma, H: Accelerated intimai hyperplasia and increased endogenous inhibitors for NO synthesis in rabbits with alloxan-induced hyperglycaemia. Br J Pharmacol 126: 211-218, 1999
3. Boger RH, Bode-Boger SM, Tsao PS, Lin PS, Chan JR, Cooke JP: An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol 36: 2287-2295, 2000
4. Kielstein JT, Impraim B, Simmel S, Bode-Boger SM, Tsikas D, Frolich JC, Hoeper MM, Haller H, Fliser D: Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 109: 172-177, 2004
5. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, Vallance P: Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 23: 1455-1459, 2003
6. Vallance P, Leiper J: Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 24:1023-1030, 2004
7. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frolich J, Boger R: Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study. Lancet 358: 2113-2117, 2001
8. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS; AIPRD Study Group: Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level meta-analysis. Ann Intern Med 139: 244-252, 2003
9. Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW, Rogers NL, Teschan PE: Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 51: 1908-1919, 1997
10. McClellan WM, Flanders WD: Risk factors for progressive chronic kidney disease. J Am Soc Nephrol 14[Suppl]: S65-S70, 2003
11. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, Whelton PK, He J: The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 140: 167-174, 2004
12. Stuhlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, Reaven GM, Tsao PS: Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 287: 1420-1426, 2002
13. Kielstein JT, Simmel S, Bode-Boger SM, Roth HJ, Schmidt-Gayk H, Haller H, Fliser D: Subpressor dose asymmetric dimethylarginine modulates renal function in humans through nitric oxide synthase inhibition. Kidney Blood Press Res 27: 143-147, 2004
14. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T: Endogenous nitric oxide synthase inhibitor: A novel marker of atherosclerosis. Circulation 99: 1141-1146, 1999
15. Zoccali C, Benedetto FA, Maas R, Mallamaci F, Tripepi G, Malatino LS, Boger R; CREED Investigators: Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol 13: 490-496, 2002
16. Tracy RE, MacLean CJ, Reed DM, Hayashi T, Gandia M, Strong JP: Blood pressure, nephrosclerosis, and age autopsy findings from the Honolulu Heart Program. Mod Pathol 1: 420-427, 1988
17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461-470, 1999
18. Schulze F, Wesemann R, Schwedhelm E, Sydow K, Albsmeier J, Cooke JP, Boger RH: Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med 42: 1377-1383, 2004
19. Lunn M, McNeil D: Applying Cox regression to competing risks. Biometrics 51: 524-532, 1995
20. Hosmer DW, Lemeshow LS: Other model and topics. In: Applied Survival Analysis, Regression Modelling of Time to Event Data, New York, John Wiley & Sons, 1999, pp 308-317
21. Kleinbaum DG: Extension of the Cox proportional hazard model for time-dependent variables. In: Survival Analysis, a Self-Learning Text, New York, Springer-Verlag, 1996, pp 211-254
22. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42: 1206-1252, 2003
23. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21: 1011-1053, 2003
24. Kannel WB, Stampfer MJ, Castelli WP, Verter J: The prognostic significance of proteinuria: The Framingham study. Am Heart J 108: 1347-1352, 1984
25. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, Klag MJ, Mailloux LU, Manske CL, Meyer KB, Parfrey PS, Pfeffer MA, Wenger NK, Wilson PW, Wright JT Jr: Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 32: 853-906, 1998
26. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW: Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108: 2154-2169, 2003
27. Cooke JP: Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 20: 2032-2037, 2000
28. Calver A, Collier J, Leone A, Moncada S, Vallance P: Effect of local intra-arterial asymmetric dimethylarginine (ADMA) on the forearm arteriolar bed of healthy volunteers. J Hum Hypertens 7: 193-194, 1993
29. Tran CT, Leiper JM, Vallance P: The DDAH/ADMA/NOS pathway. Atheroscler Suppl 4: 33-40, 2003
30. Smirnova IV, Kajstura M, Sawamura T, Goligorsky MS: Asymmetric dimethylarginine upregulates LOX-1 in activated macrophages: Role in foam cell formation. Am J Physiol Heart Circ Physiol 287: H782-H790, 2004
31. Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339: 572-575, 1992
32. Fujiwara N, Osanai T, Kamada T, Katoh T, Takahashi K, Okumura K: Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension: Modulation of nitric oxide synthesis by salt intake. Circulation 101: 856-861, 2000
33. Scuteri A, Stuehlinger MC, Cooke JP, Wright JG, Lakatta EG, Anderson DE, Fleg JL: Nitric oxide inhibition as a mechanism for blood pressure increase during salt loading in normotensive postmenopausal women. J Hypertens 21: 1339-1346, 2003
34. Tarnow L, Hovind P, Teerlink T, Stehouwer CD, Parving HH: Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 27: 765-769, 2004
35. Sims RJ, Cassidy MJ, Masud T: The increasing number of older patients with renal disease. BMJ 327: 463-464, 2003
36. Laposata M: SI Unit Conversion Guide, Robquest Print Ltd., Ashford, Kent, England, 1992